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Abstract
Background The treatment of metastatic castration-resis-
tant prostate cancer has changed with the introduction of
radium-223, cabazitaxel, abiraterone and enzalutamide. To
assess value for money, their cost effectiveness in patients
with metastatic castration-resistant prostate cancer previ-
ously treated with docetaxel from the Dutch societal per-
spective was investigated.
Methods A cost-effectiveness analysis was conducted
using efficacy, symptomatic skeletal-related event and
safety data obtained from indirect treatment comparisons.
Missing skeletal-related event data for cabazitaxel were
conservatively assumed to be identical to radium-223.
A Markov model combined these clinical inputs with
Dutch-specific resource use and costs for metastatic cas-
tration-resistant prostate cancer treatment from a societal
perspective. Total quality-adjusted life-years and costs in
2017 euros were calculated over a 5-year (lifetime) time
horizon.
Results Radium-223 resulted in €6092 and €4465 lower
costs and 0.02 and 0.01 higher quality-adjusted life-years
compared with abiraterone and cabazitaxel, respectively,
demonstrating dominance of radium-223. Sensitivity
analyses reveal a 64% (54%) chance of radium-223 being
cost effective compared with abiraterone (cabazitaxel) at
the informal €80,000 willingness-to-pay threshold. Com-
pared with enzalutamide, radium-223 resulted in slightly
lower quality-adjusted life-years (-0.06) and €7390 lower
costs, revealing a 61% chance of radium-223 being cost
effective compared with enzalutamide. The lower costs of
radium-223 compared with abiraterone and enzalutamide
are driven by lower drug costs and prevention of expensive
skeletal-related events. Compared with cabazitaxel, the
lower costs of radium-223 are driven by lower costs of the
drug, administration and adverse events.
The original version of the article was revised due to retrospective
open access order.
Presented at the European Cancer Congress on 27 September, 2015 in
Vienna, Austria, at the International Society For Pharmacoeconomics
and Outcomes Research 18th Annual European Congress on the 9
November, 2015 in Milan, Italy, and at the Nederlandse Vereniging
voor Nucleaire Geneeskunde Meeting on the 20 May, 2016 in
Eindhoven, The Netherlands.
Electronic supplementary material The online version of this
article (doi:10.1007/s40258-017-0350-x) contains supplementary
material, which is available to authorized users.
& Jennifer G. Gaultney
jgaultney@mapigroup.com
1 Real World Strategy and Analytics, Mapi Group, Houten,
The Netherlands
2 Bayer B.V., Mijdrecht, The Netherlands
3 Department of Nuclear Medicine, Catharina Ziekenhuis,
Eindhoven, The Netherlands
4 Department of Nuclear Medicine and Molecular Imaging,
University of Groningen, University Medical Centre
Groningen, Groningen, The Netherlands
5 Department of Urology, University of Groningen, University
Medical Centre Groningen, Groningen, The Netherlands
6 Department of Internal Medicine, Albert Schweitzer
Ziekenhuis, Dordrecht, The Netherlands
7 Department of Internal Medicine, Tergooi Ziekenhuizen,
Hilversum, The Netherlands
8 Real World Strategy and Analytics, Mapi Group, The
Translation and Innovation Hub Building, 5th Floor, 80
Wood Lane, White City, London W12 OBZ, UK
Appl Health Econ Health Policy (2018) 16:133–143
https://doi.org/10.1007/s40258-017-0350-x
Conclusion Radium-223 may be a less costly treatment
strategy offering similar gains in health benefits compared
with abiraterone, cabazitaxel and enzalutamide in patients
with metastatic castration-resistant prostate cancer previously
treated with docetaxel from the Dutch societal perspective.
Key Points for Decision Makers
While offering similar health gains, radium-223 may
be a less costly treatment strategy compared with
abiraterone followed by cabazitaxel and
enzalutamide in patients with metastatic castration-
resistant prostate cancer previously treated with
docetaxel.
The lower costs of radium-223 are mainly driven by
lower drug costs and prevention of expensive
symptomatic skeletal events.
1 Introduction
Castration-resistant prostate cancer (CRPC) is an incurable
form of prostate cancer resistant to surgical or pharma-
ceutical castration that occurs when the disease progresses
despite castration levels of androgens. It is termed meta-
static CRPC (mCRPC) when the disease has developed
(bone) metastases [1–4]. Morbidity from complications of
these bone metastases, i.e. symptomatic skeletal-related
events (SSEs) such as pathologic fractures, spinal cord
compression and pain, greatly impairs the quality of life of
patients with mCRPC [5].
The Dutch incidence rate of prostate cancer in 2014 was
119 new cases per 100,000 men (preliminary estimate). The
10-year prevalence in 2013 was 73,639 [6]. About 3800
patients per year are diagnosed with metastatic, hormone-
sensitive prostate cancer and despite hormonal therapy
around 75% of these patients will progress to mCRPC, with
themedian time to progression ranging from18 to 24 months
[7]. These patients have a poor prognosis, and are expected to
survive B19 months [8]. The standard of care for mCRPC
progressing on androgen deprivation therapy has tradition-
ally been docetaxel, with few therapeutic options for patients
progressing. The treatment landscape of mCRPC has chan-
ged with the introduction of cabazitaxel (CA), abiraterone
acetate (AA), enzalutamide (EN) and radium-223 (Ra-223),
expanding the number of treatment options available and
providing several additional months of survival [9].
Radium-223 is licensed in Europe for the treatment of
adult patients with CRPC with symptomatic bone
metastases and no visceral metastases [10]. The efficacy
and safety of Ra-223 have been evaluated in a double-
blind, randomised, multinational, phase III study of Ra-223
(ALSYMPCA) for the treatment of patients with mCRPC
who had either received docetaxel previously or were
unwilling or unfit to receive docetaxel. Patients included in
the trial were required to have two or more bone metastases
detected on skeletal scintigraphy, a life expectancy of at
least 6 months and no known visceral metastases or a
malignant lymphadenopathy more than 3 cm in diameter.
In the ALSYMPCA trial, Ra-223 improved the median
overall survival (OS) by 3.6 months (hazard ratio = 0.695;
p\ 0.001) and prolonged the median time to SSE by
5.8 months (hazard ratio = 0.658; p\ 0.001) compared
with placebo [11]. In the ALSYMPCA trial, the quality-of-
life benefit associated with Ra-223 was greatest in the
stable disease and pre-SSE setting, suggesting that delaying
the occurrence of the first SSE is associated with a better
quality of life [12, 13].
With the approval of new therapies, the costs of the
management of mCRPC are increasing. Although the OS
benefit of these innovative drugs has been well investi-
gated, little is known about their cost effectiveness. Given
the significant costs, the impact of SSEs on quality of life
and the differences in SSE rates between treatments, an
economic evaluation of the treatment landscape of patients
with mCRPC with prior docetaxel treatment is warranted
[5, 11–16]. KWF Kankerbestijding recently reported on the
problems surrounding the financing of new cancer treat-
ments and highlighted the importance of costs and of
insight into the cost effectiveness of new treatments [17].
This study focuses purely on the post-docetaxel setting of
mCRPC on account of the potential to introduce an unac-
ceptable risk of bias when pooling data across patient
populations studied in the docetaxel-naive setting of the
trials for AA, EN and Ra-223, which differed significantly
in terms of disease severity and prognosis. The aim of this
study was to investigate the cost effectiveness of Ra-223
compared with CA, AA and EN, all in combination with
the best standard of care, in patients with mCRPC previ-




Patients with mCRPC despite prior docetaxel treatment as
treated in the ALSYMPCA trial were the focus of this
study. The baseline characteristics of these patients have
been described elsewhere [11].
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2.2 Comparative Treatment
The choice of comparators was based on a systematic lit-
erature review of the latest clinical trials in mCRPC and the
Dutch guideline for mCRPC in the post-docetaxel setting,
and was validated by experts in the mCRPC treatment field
[3]. Only comparators that, like Ra-223, have a proven
effect on OS and are recommended for systemic therapy
for mCRPC in the post-docetaxel setting, were included in
the model. Other treatments such as samarium-153-
EDTMP, strontium-89-chloride and rhenium-188-HEDP
are only recommended for the treatment of pain (i.e. best
supportive care) as they do not have a proven effect on OS
[3]. In the systematic literature review, MEDLINE,
MEDLINE In-Process, EMBASE and the Cochrane
Library were searched in January 2014 [see Electronic
Supplementary Material (ESM) for search details]. The
search was restricted to records published from January
2000 onwards. Study selection took place based on pre-
defined criteria regarding the population, interventions,
outcomes and study design of interest. The population of
interest consisted of adult patients with CRPC. The inter-
ventions of interest were Ra-223, AA, CA, EN, sipuleucel-
T, docetaxel, best supportive care, strontium-89, samar-
ium-153, sunitinib, zibotentan, mitoxantrone and deno-
sumab. Randomised controlled trials reporting clinical,
quality of life, resource use and work productivity out-
comes were of interest.
In the model, three comparisons were conducted: (1)
Ra-223 vs. AA; (2) Ra-223 vs. CA; and (3) Ra-223 vs. EN.
All comparators were administered in combination with
best standard of care. The definition of best standard of
care was based on the control arm of the ALSYMPCA trial
and includes local external beam radiation, corticosteroids,
antiandrogens, oestrogens (e.g. stilboestrol), estramustine
or ketoconazole [11].
2.3 Analytic Specifications and Model Structure
A cost-utility analysis from the Dutch societal perspective
including direct healthcare costs, direct non-medical costs
of informal care and indirect costs owing to productivity
loss was designed to estimate the costs and health out-
comes incorporating improvements in the quality of life on
survival. A cost-utility analysis was chosen given the
impact of SSEs on quality of life and the differences in SSE
rates between the selected comparators [5, 11–16]. In line
with best practice for oncology modelling and the clinical
trial, a Markov model was built to capture the transition of
patients with mCRPC through clinically meaningful health
states along the disease management pathway. The model
was validated in accordance with the AdViSHE validation-
assessment tool [18] (see ESM). The model structure and
input data were validated for the Dutch clinical perspective
by four clinical experts treating daily practice patients in
the Netherlands; similarly, the model outcomes were val-
idated by six other clinical experts also treating daily
practice patients in the Netherlands. A time horizon of
5 years was employed, which can be considered lifetime,
given the short life expectancy of the patient population.
Five health states are included: (1) progression-free sur-
vival (PFS) without SSE; (2) PFS with SSE; (3) progressed
without SSE; (4) progressed with SSE; and (5) death
(Fig. 1). Prostate-specific antigen levels were used to
measure disease progression, defined as an increase of
C25% from baseline level at C12 weeks in patients with
no decrease from baseline; or an increase of C25% in the
level above the nadir, confirmed C3 weeks later in patients
with an initial decrease from baseline [11]. A SSE was
defined as a pathologic bone fracture, spinal cord com-
pression, external beam radiation or surgical intervention.
Transitions between states occur within a cycle length of
1 week.
Patients enter the model in the ‘PFS without SSE’ health
state and over time either remain in this state or transition
to ‘PFS with SSE’, ‘progressive without SSE’, ‘progressed
with SSE’ or ‘death’ in a later stage. Once a patient
experiences an event of progression or SSE, it is not pos-
sible to transition back to the previous state. Therefore,
patients in the ‘PFS with SSE’ will either remain in this
state or transition to ‘progressed with SSE’ or ‘death’, and
patients in the ‘progressed without SSE’ will either remain
in this state or transition to ‘progressed with SSE’ or
‘death’. Finally, patients in the ‘progressed with SSE’ may
only remain in this state or transition to ‘death’.
2.4 Clinical Inputs
Efficacy and safety data for Ra-223, AA, CA and EN were
based on the ALSYMPCA, COU-AA-301, TROPIC and
















Fig. 1 Markov model structure. PFS progression-free survival, SSE
symptomatic skeletal-related event
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probabilities for movement between health states for Ra-
223 were based on patient-level data from the
ALSYMPCA trial, specifically the OS, PFS and SSE event-
free survival data [11]. Clinical data were extrapolated
beyond the period of the trial. Data from Kaplan–Meier
curves were used to formulate different survivor functions,
representing the risk of death, progression or SSE event
over time (see ESM for details on the survival analysis
methods). To select the appropriate distribution for the
survival curves, three proportional hazard rate functions
(i.e. Exponential, Gompertz and Weibull), and two accel-
erated-failure-time functions (i.e. Log-Logistic and Log-
Normal) were fitted to the Kaplan–Meier curves from both
treatment arms. As visual inspection of the curves may be
inaccurate, the Akaike Information Criterion was used to
determine which parametric curve better fits the Kaplan–
Meier data. The log-normal distribution was fitted to the
Kaplan–Meier curves for OS and PFS both in the placebo
(best standard of care) and Ra-223 arms based on good-
ness-of-fit tests using the lowest Akaike Information Cri-
terion. For the incidence of SSE, which was based on SSE
event-free survival, the best fit was the log-logistic distri-
bution. To define the parametric survival model beyond the
duration of the trial, the parameters of each fitting curve
were extrapolated. As no patient-level data were available
for the selected comparators for treatment of patients with
mCRPC, data on hazard ratios for OS and PFS reported in
the trials studying the selected comparators vs. BSC were
obtained by means of a systematic literature review. For
SSE event-free survival, there were no hazard ratios
available in the systematic literature review and therefore a
conservative assumption was made that the extrapolated
SSE event-free survival was similar across the comparators
and equal to that for Ra-223. Comparative effectiveness in
terms of OS and PFS between the intervention and com-
parators was performed by evidence synthesis methods
based on the common treatment arm BSC. An indirect
treatment comparison by means of a Bayesian network
meta-analysis was performed in WinBUGS on the hazard
ratio for OS and PFS (see ESM for details on the network
meta-analysis methods). The hazard ratios were applied to
the parametric functions chosen for Ra-223 to derive the
transition probabilities for the selected comparators. Given
the impossibility to apply a hazard ratio to the PFS curves
based on the alkaline phosphatase test (log-normal and log-
logistic), the use of the Weibull form was chosen as the
most appropriate for comparisons of OS and PFS to other
active agents as it is the best fitting curve by means of the
Akaike Information Criterion among the proportional
hazard rate functions. All clinical inputs can be found in
the ESM.
Active treatment dosing was obtained from the respec-
tive summaries of product characteristics for Ra-223, AA,
CA and EN. Patients treated with Ra-223 and CA were
assumed to receive in total five and six injections,
respectively, in line with the mean treatment duration
observed in the respective phase III studies [15, 19].
Symptomatic skeletal-related event data related to Ra-223,
AA and EN were obtained from the respective pivotal trials
(Table 1) [20–22]. As SSE data related to CA were not
available, these were conservatively assumed to be iden-
tical to Ra-223.
2.5 Utility Inputs
Health-state utilities for Ra-223 were derived directly from
the health-related quality-of-life data collected in the
ALSYMPCA trial (see the ESM) [11]. Utility data for AA,
CA and EN were not available in the literature; therefore,
these were conservatively assumed to be identical to those
for Ra-223. In the trial, patients were asked to complete the
EQ-5D at the baseline visit and at all the follow-up visits.
Scores from each EQ-5D category were used to create a
single utility index score using population-specific weights
(UK population weights). Health-state utilities used in the
model are assumed to reflect disutilities from adverse
events patients experienced during the trial. Therefore,
including additional disutilities for adverse events may
result in double counting and their exclusion was consid-
ered a conservative assumption given the better safety
profile of Ra-223 compared with AA, CA and EN
[11, 14–16]. This better safety profile is also reflected in the
higher European Society for Medical Oncology Magnitude
of Clinical Benefit Scale for Ra-223 than for AA, CA and
EN [23].
2.6 Resource Use and Cost Inputs
Three cost categories were considered: (1) direct medical
costs inside the health system, including drug acquisition
costs, outpatient and inpatient visits costs, treatment
administration, monitoring and adverse event management
costs, and costs of treating SSEs; (2) direct non-medical
costs outside the healthcare system, including informal
caregiver costs; and (3) indirect non-medical costs,
including productivity loss (see the ESM). All costs were
inflated to 2017 euros using inflation rates published by
Statistics Netherlands [24].
Resource use data specific to the Dutch clinical setting
were gathered from Dutch hospital treatment protocols and
during an advisory boardwith key opinion leaders in the field
of treatment for mCRPC. Four clinical experts in the fields of
oncology, urology and nuclear medicine participated in the
advisory board on 18 September, 2014 During the advisory
board, 20 specific questions were discussed; consensus on
these questions was reached through deliberation. The
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advisory board resulted in a consensus report that was
approved by all participants. In addition, resource use data
were gathered in an interview with an expert involved in the
Castration-resistant Prostate Cancer Registry, a real-world
outcomes database in the Netherlands. In the case of
important differences, the average of the data gathered from
the advisory board and from the Castration-resistant Prostate
Cancer Registry was used [25].
The number of physician outpatient visits and visits for
monitoring procedures was calculated based on expert
opinion elicited during the advisory board. Unit costs for
drug acquisition, administration including outpatient visits,
monitoring procedures, including computed tomography
scan and laboratory tests were retrieved from published
sources [26–28], validated by Dutch key opinion leaders in
the field of mCRPC treatment and conform to the Dutch
guidelines on cost research [28].
Healthcare utilisation associated with adverse event man-
agement, including the proportion of patients requiring hos-
pitalisation and unit costs,was based on theALSYMPCA trial
for Ra-223 and the local reimbursement submission dossier
for AAor on expert opinionwhen no datawere available [29].
The costs related to the treatment of SSEs were obtained from
Carter et al. [30]. It was assumed that 39% of patients required
end-of-life care (i.e. hospice) based onMeeussen et al. with an
average duration of 3 months based on expert opinion [31].
The remaining 61% were assumed to require daily visits by a
nurse based on Meeussen et al., with an average duration of
3 months based on expert opinion [31].
The direct non-medical costs included in the model were
informal caregiver costs. Other direct non-medical costs
such as travel expenses were not included in the model, as
no relevant differences in travel costs were expected
between treatment groups based on expert opinion. Travel
expenses are also minor in comparison to direct medical
costs and are therefore assumed to have a negligible impact
on the model results. Indirect costs owing to productivity
loss are included in the model based on expert opinion and
were calculated by means of the friction cost method as
required by the Dutch guidelines [28, 32].
2.7 Outcomes
The main outcomes of the cost-utility analysis included
total and incremental costs, health benefits in terms of total
and incremental quality-adjusted life-years (QALYs) and
life-years (LY) gained, and incremental cost-effectiveness
ratios (ICERs). The ICERs were calculated as the differ-
ence in total costs between Ra-223 and selected compara-
tors divided by the difference in the number of QALYs or
the difference in LYs, resulting in the incremental cost per
QALY and LY gained, respectively. Total costs and health
benefits were discounted at 4 and 1.5%, respectively,
according to Dutch guidelines [32].
2.8 Sensitivity Analysis
A one-way sensitivity analysis was conducted to assess the
impact of varying model inputs on the ICER. The param-
eters included in the one-way sensitivity analysis were:
parameters of the parametric survival curves for OS and
PFS, utility inputs, duration of therapy, cost items, discount
rates for costs and outcomes and time horizon. A proba-
bilistic sensitivity analysis (PSA) was also performed to
Table 1 Frequency and costs of treating symptomatic skeletal-related events (SSEs) per comparator [20–22, 30]








Incidence of SSE Incidence of SSEs was based on Kaplan–Meier curve extrapolations of SSE free survival
data and assumed the same across all comparators owing to a lack of data
Recurrence of SSEb 100 100 100
Distribution of SSE type
Pathologic bone
fracture





10 19 24 10,960
External beam
radiation
73 61 63 2171
Surgical intervention 5 4 2 19,896
AA abiraterone acetate, CA cabazitaxel, EN enzalutamide, Ra-223 radium-223
a Costs were taken from Carter et al. [30] and inflated to 2017 euros using inflation rates published by Statistics Netherlands [24]
b Probability of recurrence was assumed to be 100% based on expert opinion that all patients with an SSE will have a recurrence
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assess the joint uncertainty of all parameters on the cost-
effectiveness results. The PSA was conducted by running
1000 simulations and applying the willingness-to-pay
threshold at €80,000 per QALY gained, the informal pro-
posed Dutch threshold for diseases of high severity [33].
The following parameters were analysed in the PSA:
parameters of the parametric survival curves for OS and
PFS (lognormal distribution), utility inputs (beta distribu-
tion), duration of therapy (gamma distribution), and the
costs of treating adverse events grade 3 and 4 (gamma
distribution) and SSEs (gamma distribution). The upper
and lower distribution values can be found in the ESM.
3 Results
3.1 Health Benefits
Over the 5-year (lifetime) time horizon of the model, Ra-
223 yielded a total of 0.8 QALYs and 1.39 LYs. In com-
parison, AA yielded 0.78 QALYs and 1.36 LYs, CA
yielded 0.79 QALYs and 1.38 LYs, and EN yielded 0.86
QALYs and 1.50 LYs (Table 2). Ra-223 was associated
with fewer SSEs than AA and with fewer severe SSEs than
EN (Table 1).
3.2 Costs
Compared with AA, Ra-223 accrued €6092 lower lifetime
costs (Table 2). The lower costs of Ra-223 compared with
those of AA are driven by lower drug and SSE treatment
costs (Fig. 2). The lower costs for SSEs are associated with
a lower frequency of more severe, and hence more costly,
SSEs in Ra-223- than in AA-treated patients.
Compared with CA, Ra-223 accrued €4465 lower lifetime
costs over the 5-year (lifetime) time horizon of the model
(Table 2). The lower costs of Ra-223 compared with those of
CA are driven by lower drug, administration and adverse
event costs (Fig. 2).Taking into account that the SSE rates
were assumed to be identical for Ra-223 and CA, the lower
costs achieved with Ra-223 could be underestimated.
Compared with EN, Ra-223 accrued €7390 lower life-
time costs (Table 2). The lower costs of Ra-223 compared
with those of EN are driven by lower drug and SSE
treatment costs (Fig. 2). The latter is associated with a
lower frequency of more severe, and hence more costly
SSEs in Ra-223- than in EN-treated patients.
3.3 Incremental Costs per Health Gain
Ra-223 dominates AA followed by CA, with lower costs
and higher QALYs and LYs. Compared with EN, Ra-223
was slightly less effective but also less costly (Table 2)
3.4 One-Way Sensitivity Analysis
The results of the one-way sensitivity analysis demonstrate
that, across all comparisons, the most influential parame-
ters include the hazard ratio for OS, duration of therapy,
utility for ‘progressed without SSE’, non-medical costs (i.e.
productivity costs and informal care), the cost of managing
spinal cord compression and the utility for ‘PFS without
SSE’ (see the ESM).
3.5 Probabilistic Sensitivity Analysis
At a willingness-to-pay threshold of €80,000, the PSA
reveals a 54% chance of Ra-223 being cost effective
compared with CA, a 64% chance compared with AA and a
61% chance compared with EN (Fig. 3).
4 Discussion
This study shows that in the post-chemotherapy setting the
effectiveness of Ra-223, in terms of QALYs and LYs, is
comparable to CA, AA and EN. This is in line with the
Dutch criteria assessing the value of new oncolytic
medicines, showing that there is no clinically meaningful
difference in the efficacy of Ra-223, AA, CA and EN
[33, 34]. The lifetime costs of patients with mCRPC in the
Netherlands are lower for Ra-223 than for its comparators,
mainly driven by lower drug and SSE costs. Therefore, Ra-
223 may be a less costly treatment strategy compared with
AA, CA and EN in Dutch patients with mCRPC previously
treated with docetaxel.
This is the first study to investigate the cost effectiveness
of Ra-223 compared with AA, CA and EN in the post-
docetaxel setting in the Netherlands. The results reported
here provide valuable insights that can inform decisions on
the reimbursement of these medications in the Netherlands
and on the allocation of oncology budgets within hospitals
and healthcare insurers.
To compare with previous studies, a systematic search
of the literature was performed identifying one full-text
publication describing economic evaluations for AA, CA
and/or EN in the post-docetaxel setting of mCRPC [35].
However, as the study by Zhong et al. employed an
18-month time horizon, compared with a lifetime time
horizon in this study, no comparison of the results can be
made. Fifteen conference abstracts describing such analy-
ses were additionally identified [36–50], but as these only
provide limited data and barely any information on the
methods employed, no informed comparisons with the
results from this study can be made.
The results of this study can nonetheless be compared
with those reported for AA and CA in the Dutch
138 M. L. Peters et al.





















Ra-223 78,318 – 1.39 – 0.8 –
AA 84,410 -6092 1.36 0.03 0.78 0.02 Ra-223 dominates
AA
CA 82,783 -4465 1.38 0.01 0.79 0.01 Ra-223 dominates
CA
EN 85,708 -7390 1.5 -0.11 0.86 -0.06 Ra-223 slightly
less effective and
less costly
Costs are displayed in 2017 euros
AA abiraterone acetate, CA cabazitaxel, EN enzalutamide, LY life-year, QALY quality-adjusted life-year, Ra-223 radium-223
Fig. 2 Lifetime costs
breakdown per comparison. AA
abiraterone acetate, AE adverse
event, CA cabazitaxel, EN
enzalutamide, mCRPC
metastatic castration-resistant
prostate cancer, Ra-223 radium-
223, SSE symptomatic skeletal-
related event. Costs are




acetate, CA cabazitaxel, EN
enzalutamide, QALY quality-
adjusted life-year, Ra-223
radium-223. Costs are displayed
in 2017 euros
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reimbursement process for mCRPC treatments. In 2011,
the Dutch National Health Care Institute advised that CA
can be added to the policy regulation expensive medica-
tions for the treatment of mCRPC that progresses on doc-
etaxel [51]. The included pharmacoeconomic evaluation
compared the cost effectiveness of CA with mitoxantron
from a societal perspective over a lifetime time horizon.
Treatment with CA yielded 1.5 LYs and 0.864 QALYs
with an associated cost of €46,247 (in 2011 euros) per
patient [51]. This result is comparable to the 1.38 LYs, 0.79
QALYs and €82,783 cost (in 2017 euros) that CA yielded
in this study.
More recently, in 2012, the Dutch National Health Care
Institute assessed AA and determined it to have equal ther-
apeutic value to CA with higher expected costs. This nor-
mally would have resulted in a negative advice. However,
the European Medicines Agency regarded AA as a valuable
new therapy, and themCRPCmarket was still changing after
the positive assessment of CA, resulting in a more uncertain
cost estimate. Therefore, the Dutch National Health Care
Institute advised reimbursement of AA for the treatment of
mCRPCwith disease progression despite previous docetaxel
treatment [29]. The included pharmacoeconomic evaluation
compared the cost effectiveness of AA plus prednisone with
CA plus prednisone and prednisone monotherapy from a
healthcare perspective over a lifetime time horizon. Treat-
ment with AA yielded 1.41 LYs and 1.1 QALYs with an
associated direct medical cost of €37,297 (in 2010 euros) per
patient. Treatment with CA yielded 1.34 LYs and 1.03
QALYswith an associated direct medical cost of €32,915 (in
2010 euros) per patient [29]. The result in LYs is comparable
to the 1.46 LYs for AA and 1.38 LYs CA yielded in this
study. However, the QALYs differ from the 0.78 QALYs for
AA and 0.79 QALYs for CA in this study. This can be
explained by the use of higher health states utility values in
the analysis submitted in the pharmacoeconomic dossier for
AA (0.80 for baseline and 0.715 for post-progression)
comparedwith this study (0.617 and 0.511, respectively). No
comparison of costs can be made owing to the difference in
analysis perspective, i.e. healthcare vs. societal perspective.
Finally, no report has been published for EN by the Dutch
National Health Care Institute.
Regarding reimbursement decisions outside the
Netherlands, the National Institute for Health and Care
Excellence recently recommended Ra-223 in the UK as an
option for treating adults with mCRPC and no known
visceral metastases in the post-docetaxel setting under a
patient access scheme. For patients who had previously
received docetaxel, the committee concluded that the ICER
for Ra-223 compared with AA fell within the accept-
able range, with Ra-223 dominating AA in the base-case
analysis, and that Ra-223 could be considered cost effec-
tive [52, 53].
The National Institute for Health and Care Excellence
has expanded the treatment scope based on an updated
cost-effectiveness analyses performed by Bayer comparing
Ra-223 with the current care available for people con-
traindicated for docetaxel, and for whom docetaxel is
unsuitable and concluded that the use of Ra-223 is cost
effective in this pre-docetaxel setting [49]. In the Nether-
lands, first-line use of Ra-223 in a pre-docetaxel setting is
included in the recommendations for chemotherapy-fit and
chemotherapy-unfit patients with mCRPC with symp-
tomatic bone metastases and no visceral metastases [50].
A few limitations to the study methods deserve men-
tioning. First, the analysis is limited to the post-docetaxel
setting of mCRPC on account of important differences
between the patient populations in the docetaxel-naive
setting of the trials for AA, CA, EN and Ra-223 in terms of
disease severity and prognosis. Pooling these data in a
modelling study would introduce an unacceptable risk of
bias. However, the docetaxel-naive setting is also of
interest and therefore further research into the cost effec-
tiveness of AA, EN and Ra-223 in the docetaxel-naive
setting of mCRPC is warranted.
Second, the results from this study are derived from
patients treated in a trial setting, which may not always
reflect the clinical setting in Dutch daily practice. However,
the data were derived from patients treated under the same
conditions in a trial setting, allowing these treatments to be
more easily compared than when using real-world data.
Additionally, the trials that provided the model inputs were
similar in terms of baseline characteristics and prognosis
[11, 14–16], which is not often the case with real-word
data, where confounding by indication is a risk, particularly
in oncology.
Currently, data from clinical trials are the best available
evidence for comparative effectiveness of treatments for
mCRPC patients in the Netherlands. Therefore, the indirect
treatment comparison by means of a network meta-analysis
was the best option is this situation, as it combined direct and
indirect evidence on the relative treatment effects while
minimising bias. When real-world patient data become
available, the analysis could be updated to estimate the cost
effectiveness of AA, CA, EN and Ra-223 based on patient-
level data, with caution applied to the interpretation of such
results given the limitations associated with real-world data.
5 Conclusion
To conclude, radium-223 may be a less costly treatment
strategy offering similar gains in health benefits compared
with abiraterone, cabazitaxel and enzalutamide in mCRPC
patients previously treated with docetaxel from the Dutch
societal perspective.
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